Navigation Links
Study supports safety of antimicrobial peptide-coated contact lenses
Date:4/24/2014

Philadelphia, Pa. (April 24, 2014) - Contact lenses coated with an antimicrobial peptide could help to lower the risk of contact lens-related infections, reports a study in Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Studies in animals and now humans support the biocompatibility and safety of lenses coated with the antimicrobial peptide melimine, according to the new research by Debarun Dutta, B.Optom, of The University of New South Wales, Sydney, and colleagues. They write, "[T]his study has shown that melimine coated contact lenses can be safely worn by humans without any major side effects."

Synthetic Coating Designed to Mimic Natural Infection-Fighting Peptides

The researchers performed a series of experiments to evaluate the safety of contact lenses coated with melimine, designed to reduce the risk of inflammation and infections. Melimine is not an antibioticrather, it is a "cationic peptide" with broad-spectrum antimicrobial activity.

"Antimicrobial peptides are small peptides and part of the innate immune system of all multicellular organisms with the native ability to inhibit microbial growth," Dr Dutta and colleagues explain. Melimine is among the first antimicrobial peptides to be tested for clinical use. The study used conventional disposable contact lenses to which melimine was molecularly (covalently) bonded.

Studies in rabbits supported the safety of melimine-coated contact lenses for up to three weeks. There were no signs of toxic effects on the eye, either in terms of inflammation/infection or on the cellular level.

In a subsequent study, human volunteers wore melimine-coated or conventional contact lenses for one day. The coated and uncoated lenses had similar characteristics, including wettability, surface deposits, lens fitting on the center of the eye, lens movement and tightness, and coverage of the cornea. Importantly, there were no differences in redness of the eyean early sign of irritation or inflammation.

No Signs of Safety Problems with Melimine-Coated Lenses in Human Eye

The only significant difference was increased staining of the cornea (the clear outer layer of the eye) caused by melimine-coated lenses. Comfort ratings were similar between the two lensesjust one volunteer reported discomfort with the coated lenses.

No delayed reactions occurred after wearing melimine-coated lenses. The day after they were worn, the lenses were still active against Pseudomonas and Staphylococcus bacteria in culture.

Wearing contaminated contact lenses can cause redness and inflammation of the eye, leading to rare but potentially serious infections. "A contact lens with high antimicrobial activity may inhibit microbial adhesion and consequently reduce theseadverse events," Dr Dutta and coauthors write. Preliminary studies in animals have supported further research and development of contact lenses coated with melimine.

The new results add to previous data on the safety of melimine-coated lenses in animals, and provide initial evidence of their safety and comfort in humans. The lenses also show lasting antimicrobial activity. Dr Dutta and colleagues add, "Whether melimine could reduce contact lens-related adverse events during wear, especially extended wear, requires more clinical trials."

"Practitioners and researchers are hoping to develop new ways to try to reduce rare corneal infections associated with contact lens wear," comments Anthony Adams, OD, PhD, Editor-in-Chief of Optometry and Vision Science. He notes that the melimine-coated contact lenses show broad-spectrum antimicrobial properties, and appear safe and effect against Pseudmonas and Staphylococcus bacteriasome of the major "bad actors" causing corneal infections. Dr Adams adds, "While the study is one of the earlier demonstrations, it does appear to be promising."


'/>"/>

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health
Source:Eurekalert

Related medicine news :

1. Vanderbilt study finds physical signs of depression common among ICU survivors
2. Study: Altruistic adolescents less likely to become depressed
3. Pilot study suggests ways to widen access to fecal transplants for C. diff infections
4. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
5. Study identifies enzymes that help fix cancer-causing DNA defects
6. New study finds 2.5 million basketball injuries to high school athletes in 6 seasons
7. US medical innovation needs smarter incentives to cut health spending, study finds
8. First size-based chromatography technique for the study of livi
9. Male health linked to testosterone exposure in womb, study finds
10. Acute respiratory distress syndrome: Study IDs surgical patients at risk
11. Allina Health study shows information sharing between health systems reduces tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: